ClinicalTrials.gg
CompletedNCT01867125Updated Jul 17, 2026Results posted

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

A Phase 3 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 181 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,081
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
Largest of 12
1,081 · median 224
Started
2013
with 2 others
Phase 3
5 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one has the largest enrollment, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 6th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma diagnosis for greater than equal to (>/=) 12 months prior to Visit 1
  • Bronchodilator response at Visit 1, 2, or 3
  • Pre-bronchodilator of 40 percent (%) - 80% predicted at both Visits 2 and 3
  • On ICS therapy at a total daily dose of 500-2000 micrograms (mcg) of fluticasone propionate dry powder inhaler (DPI) or equivalent for >/=6 months prior to Visit 1
  • On an eligible second controller medication (long-acting beta-agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], or theophylline) for 6 months prior to Visit 1
  • Uncontrolled asthma at Visit 1 and/or Visit 2, and at Visit 3
  • Chest X-ray or computed tomography (CT) scan within 3 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 3) confirming the absence of other lung disease
  • Demonstrated adherence with controller medication during the screening period

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Maintenance oral therapy within 3 months of Visit 1
  • Treatment with systemic (oral, intravenous [IV], or intramuscular [IM]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
  • Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
  • Infection requiring hospital admission for >/=24 hours or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; Active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening; Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
  • Active tuberculosis requiring treatment within 12 months prior to Visit 1
  • Known immunodeficiency, including, but not limited to, (HIV) infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • History of interstitial lung disease, (COPD), or other lung disease other than asthma
  • Known current or current evaluation for potential malignancy
  • Current smoker or former smoker with a history of greater than (>) 10 pack-years
  • History of alcohol or drug abuse
  • Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,081 participants (actual)

Study arms

  • Experimental
    Lebrikizumab (125 mg)

    Participants will receive SC injection of lebrikizumab (125 milligrams \[mg\]) every 4 weeks for 104 weeks.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab (37.5 mg)

    Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.

    Drug: Lebrikizumab · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.

    Drug: Lebrikizumab · Drug: Placebo

Interventions

  • Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.

    Also known as: RO5490255

  • DrugPlacebo

    Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Adjusted Exacerbation Rate of Asthma During the 52-Week PCP

    Asthma exacerbation is defined as new or increased asthma symptoms (i.e., wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to systemic corticosteroid (CS) treatment (oral, intravenous (IV), or intramuscular (IM) CS for ≥ 3 days or an emergency department visit with at least one dose of IV or IM CS) or to hospitalization. Results are reported as a 'Number' representing the model-adjusted incidence rate of asthma exacerbations per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).

    Time frame: Baseline up to 52 weeks

Secondary outcomes

  1. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52

    FEV1 is the maximal amount of air, which can be forcefully exhaled in one second. Measurements were performed before use of bronchodilator. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.

    Time frame: Week 52

  2. Time to First Asthma Exacerbation During the 52-week PCP

    An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalisation. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least one dose of IV or IM corticosteroids. Reported is the time to first asthma exacerbation during the 52-week placebo-controlled period.

    Time frame: Baseline up to 52 weeks

  3. Rate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP

    Urgent health care utilization was defined as hospitalizations, emergency department visits, and acute care visits. Results are reported as a 'Number' representing the model-adjusted incidence rate of urgent asthma-related HCU events per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).

    Time frame: Baseline up to Week 52

  4. Absolute Change From Baseline in Standardized AQLQ Score at Week 52

    Asthma-specific health-related quality of life was assessed by the overall score of the Standardized AQLQ. The AQLQ is a self-administered test with 32 questions; each with seven possible answers ranging from 1 to 7 with a higher score being more favorable. Total score is calculated as follows: sum of items 1to 32 divided by 32 for a score range of 1 to 7 with a higher score indicating a better outcome. Reported is the change in AQLQ score from baseline to the end of the placebo-controlled period at Week 52.

    Time frame: Week 52

  5. Absolute Change From Baseline In Asthma Rescue Medication Use at Week 52

    Reported here is the change in the number of puffs or nebulized treatments of asthma rescue medication from baseline to the end of the PCP at Week 52.

    Time frame: Week 52

  6. Absolute Change From Baseline in ACQ-5 Score at Week 52

    The ACQ-5 is test with 5 questions; each with seven possible answers ranging from 0 to 6 with a lower score being more favorable. Total score range is 0 to 30 with a lower score indicating a better outcome. Reported is the change in ACQ-5 score from baseline to the end of the PCP at Week 52.

    Time frame: Baseline, Week 52

Other outcomes

  1. Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab

    The safety population included all participants who received at least one dose of study medication.

    Time frame: Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52 and safety follow-up [20 weeks] or end of study)

  2. Percentage of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all participants who received at least one dose of study medication.

    Time frame: Baseline up to Week 52 for Placebo arm. Week 53 to Week 104 for PBO/Lebrikizumab crossover arms. Baseline up to Week 104 for Lebrikizumab-only arms.

  3. Minimum Serum Concentration (Cmin) of Lebrikizumab

    Time frame: Predose (0 hour) at Weeks 4, 12, 24, 36, and 52

07

Results

Posted Jul 17, 2026

Participant flow

Participants with asthma, whose disease remained uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication, were recruited in 26 countries.

Placebo-Controlled Period: Weeks 1-52
Participant flow — Placebo-Controlled Period: Weeks 1-52
MilestonePlaceboLebrikizumab (37.5 mg)Lebrikizumab (125 mg)Placebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)
Started36236035900
Completed32633633500
Not completed36242400
Withdrew: Withdrawal by subject19141300
Withdrew: Adverse event65500
Withdrew: Lost to follow-up40200
Withdrew: Physician decision23100
Withdrew: Lack of efficacy21100
Withdrew: Other10200
Withdrew: Non-compliance11000
Withdrew: Death10000
Active-Treatment Extension: Weeks 53-104
Participant flow — Active-Treatment Extension: Weeks 53-104
MilestonePlaceboLebrikizumab (37.5 mg)Lebrikizumab (125 mg)Placebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)
Started0336335159157
Completed0302285139139
Not completed034502018
Withdrew: Withdrawal by subject020431315
Withdrew: Adverse event00102
Withdrew: Lost to follow-up06221
Withdrew: Other06020
Withdrew: Physician decision01010
Withdrew: Non-compliance00320
Withdrew: Lack of efficacy01100

Outcome measures

PrimaryAdjusted Exacerbation Rate of Asthma During the 52-Week PCP

Asthma exacerbation is defined as new or increased asthma symptoms (i.e., wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to systemic corticosteroid (CS) treatment (oral, intravenous (IV), or intramuscular (IM) CS for ≥ 3 days or an emergency department visit with at least one dose of IV or IM CS) or to hospitalization. Results are reported as a 'Number' representing the model-adjusted incidence rate of asthma exacerbations per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).

Time frame:
Baseline up to 52 weeks
Reported as:
Number · Asthma exacerbations per person-year
Adjusted Exacerbation Rate of Asthma During the 52-Week PCP
Asthma exacerbations per person-yearBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Adjusted Exacerbation Rate of Asthma During the 52-Week PCP0.950.460.660.600.330.44
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Poisson regression · p = 0.0198 · Rate ratio: 0.69 · 95% CI 0.51 to 0.94
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Poisson regression · p = <0.0001 · Rate ratio: 0.49 · 95% CI 0.35 to 0.69
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Poisson regression · p = 0.2051 · Rate ratio: 0.72 · 95% CI 0.44 to 1.19
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Poisson regression · p = 0.0320 · Rate ratio: 0.55 · 95% CI 0.32 to 0.95
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52

FEV1 is the maximal amount of air, which can be forcefully exhaled in one second. Measurements were performed before use of bronchodilator. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.

Time frame:
Week 52
Reported as:
Mean · millilitre (mL)
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52
millilitre (mL)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 5298 ± 25201 ± 25211 ± 2525 ± 3338 ± 32150 ± 33
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0013 · Difference in adjusted means: 113 · 95% CI 44 to 182
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0034 · Difference in adjusted means: 103 · 95% CI 34 to 172
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0070 · Difference in adjusted means: 126 · 95% CI 35 to 217
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.7782 · Difference in adjusted means: 13 · 95% CI -78 to 104
SecondaryTime to First Asthma Exacerbation During the 52-week PCP

An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalisation. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least one dose of IV or IM corticosteroids. Reported is the time to first asthma exacerbation during the 52-week placebo-controlled period.

Time frame:
Baseline up to 52 weeks
Reported as:
Median · Weeks
Time to First Asthma Exacerbation During the 52-week PCP
WeeksBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Time to First Asthma Exacerbation During the 52-week PCPNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Cox regression · p = 0.0068 · Hazard ratio (hr): 0.64 · 95% CI 0.47 to 0.89
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Cox regression · p = 0.0007 · Hazard ratio (hr): 0.58 · 95% CI 0.42 to 0.79
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Cox regression · p = 0.0435 · Hazard ratio (hr): 0.59 · 95% CI 0.35 to 0.98
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Cox regression · p = 0.0183 · Hazard ratio (hr): 0.52 · 95% CI 0.30 to 0.89
SecondaryRate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP

Urgent health care utilization was defined as hospitalizations, emergency department visits, and acute care visits. Results are reported as a 'Number' representing the model-adjusted incidence rate of urgent asthma-related HCU events per person-year. To account for early discontinuation, for each patient, the time at risk (in years) was computed as the duration of this time period (last day minus first day \[in days\] plus 1) divided by 365.25. The 'first day' was the day of randomization to the PCP. For patients entering the ATE, the 'last day' was the day prior to ATE randomization. For patients not entering the ATE, the 'last day' was at the last study visit on/prior to Study Day 379 (365 days plus a 14-day window).

Time frame:
Baseline up to Week 52
Reported as:
Number · HCU Events per person-year
Rate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP
HCU Events per person-yearBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Rate of Urgent Asthma-Related Health Care Utilization (HCU) During the 52-week PCP0.580.240.620.290.410.20
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Poisson regression · p = 0.7757 · Rate ratio: 1.06 · 95% CI 0.69 to 1.63
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Poisson regression · p = 0.0023 · Rate ratio: 0.42 · 95% CI 0.24 to 0.73
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Poisson regression · p = 0.3100 · Rate ratio: 0.69 · 95% CI 0.33 to 1.42
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Poisson regression · p = 0.2725 · Rate ratio: 1.41 · 95% CI 0.76 to 2.60
SecondaryAbsolute Change From Baseline in Standardized AQLQ Score at Week 52

Asthma-specific health-related quality of life was assessed by the overall score of the Standardized AQLQ. The AQLQ is a self-administered test with 32 questions; each with seven possible answers ranging from 1 to 7 with a higher score being more favorable. Total score is calculated as follows: sum of items 1to 32 divided by 32 for a score range of 1 to 7 with a higher score indicating a better outcome. Reported is the change in AQLQ score from baseline to the end of the placebo-controlled period at Week 52.

Time frame:
Week 52
Reported as:
Mean · Score on scale
Absolute Change From Baseline in Standardized AQLQ Score at Week 52
Score on scaleBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Absolute Change From Baseline in Standardized AQLQ Score at Week 520.78 ± 0.0640.93 ± 0.0640.91 ± 0.0640.85 ± 0.0980.73 ± 0.0960.86 ± 0.097
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.1533 · Difference in adjusted mean: 0.13 · 95% CI -0.05 to 0.31
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.1032 · Difference in adjusted mean: 0.15 · 95% CI -0.03 to 0.32
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.9293 · Difference in adjusted mean: 0.01 · 95% CI -0.26 to 0.28
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.4015 · Difference in adjusted mean: -0.12 · 95% CI -0.38 to 0.15
SecondaryAbsolute Change From Baseline In Asthma Rescue Medication Use at Week 52

Reported here is the change in the number of puffs or nebulized treatments of asthma rescue medication from baseline to the end of the PCP at Week 52.

Time frame:
Week 52
Reported as:
Mean · Puffs per day
Absolute Change From Baseline In Asthma Rescue Medication Use at Week 52
Puffs per dayBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Absolute Change From Baseline In Asthma Rescue Medication Use at Week 52-0.6 ± 0.1-1.1 ± 0.1-1.1 ± 0.1-0.8 ± 0.2-0.8 ± 0.2-1.2 ± 0.2
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0121 · Difference in adjusted means: -0.5 · 95% CI -0.9 to -0.1
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0256 · Difference in adjusted means: -0.5 · 95% CI -0.9 to -0.1
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.2698 · Difference in adjusted means: -0.4 · 95% CI -1.0 to 0.3
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.9340 · Difference in adjusted means: 0.0 · 95% CI -0.6 to 0.7
SecondaryAbsolute Change From Baseline in ACQ-5 Score at Week 52

The ACQ-5 is test with 5 questions; each with seven possible answers ranging from 0 to 6 with a lower score being more favorable. Total score range is 0 to 30 with a lower score indicating a better outcome. Reported is the change in ACQ-5 score from baseline to the end of the PCP at Week 52.

Time frame:
Baseline, Week 52
Reported as:
Mean · Score on scale
Absolute Change From Baseline in ACQ-5 Score at Week 52
Score on scaleBiomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mg
Absolute Change From Baseline in ACQ-5 Score at Week 52-0.8 ± 0.07-0.9 ± 0.06-0.9 ± 0.07-0.8 ± 0.09-0.8 ± 0.09-0.8 ± 0.09
Statistical analysis
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.4018 · Difference in adjusted mean: -0.1 · 95% CI -0.3 to 0.1
  • Biomarker-High: Placebo vs Biomarker-High: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.2341 · Difference in adjusted mean: -0.1 · 95% CI -0.3 to 0.1
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 125 mg · Mixed Model Repeated Measures (MMRM) · p = 0.9293 · Difference in adjusted mean: 0.0 · 95% CI -0.2 to 0.3
  • Biomarker-Low: Placebo vs Biomarker-Low: Lebrikizumab 37.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.9787 · Difference in adjusted mean: 0.0 · 95% CI -0.3 to 0.3
Other pre-specifiedPercentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab

The safety population included all participants who received at least one dose of study medication.

Time frame:
Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52 and safety follow-up [20 weeks] or end of study)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab
Percentage of ParticipantsPlaceboPlacebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)Lebrikizumab (37.5 mg)Lebrikizumab (125 mg)
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab011.310.818.715.1
Other pre-specifiedPercentage of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all participants who received at least one dose of study medication.

Time frame:
Baseline up to Week 52 for Placebo arm. Week 53 to Week 104 for PBO/Lebrikizumab crossover arms. Baseline up to Week 104 for Lebrikizumab-only arms.
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsPlaceboPlacebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)Lebrikizumab (37.5 mg)Lebrikizumab (125 mg)
Percentage of Participants With Adverse Events (AEs)82.378.077.793.190.0
Other pre-specifiedMinimum Serum Concentration (Cmin) of Lebrikizumab
Time frame:
Predose (0 hour) at Weeks 4, 12, 24, 36, and 52
Reported as:
Mean · microgram per millilitre (μg/mL)
Minimum Serum Concentration (Cmin) of Lebrikizumab
microgram per millilitre (μg/mL)Lebrikizumab (37.5 mg)Lebrikizumab (125 mg)
Week 4: (n= 351, 351)2.40 ± 1.678.47 ± 3.61
Week 12: (n= 352, 345)3.78 ± 2.2114.1 ± 6.17
Week 24: (n=340, 336)4.38 ± 2.2816.4 ± 7.78
Week 36: (n=335, 329)4.87 ± 3.1216.7 ± 7.62
Week 52: (n= 328, 318)4.66 ± 2.9416.9 ± 8.28

Adverse events

Collected over For the Placebo arm, the data collection period was up to 52 weeks (PCP; Weeks 1-52). For the Placebo/Lebrikizumab 37.5 mg and Placebo/Lebrikizumab 125 mg crossover arms, the data collection period was up to 52 weeks (ATE; Weeks 53-104). For the continuous Lebrikizumab 37.5 mg and Lebrikizumab 125 mg arms, the data collection period was up to 104 weeks (PCP and ATE).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/362 (0.3%)32/362 (8.8%)240/362 (66.3%)
Placebo/Lebrikizumab (37.5 mg)0/159 (0%)14/159 (8.8%)92/159 (57.9%)
Placebo/Lebrikizumab (125 mg)0/157 (0%)16/157 (10.2%)96/157 (61.1%)
Lebrikizumab (37.5 mg)0/360 (0%)48/360 (13.3%)279/360 (77.5%)
Lebrikizumab (125 mg)0/359 (0%)49/359 (13.6%)282/359 (78.6%)
Most frequent serious events
Showing 10 of 127
Most frequent serious events
EventPlaceboPlacebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)Lebrikizumab (37.5 mg)Lebrikizumab (125 mg)
AsthmaRespiratory, thoracic and mediastinal disorders6/3623/1594/15712/36011/359
PneumoniaInfections and infestations1/3623/1590/1574/3602/359
OsteoarthritisMusculoskeletal and connective tissue disorders0/3621/1592/1571/3600/359
CholelithiasisHepatobiliary disorders0/3620/1590/1573/3601/359
CellulitisInfections and infestations3/3620/1590/1570/3600/359
Atrial fibrillationCardiac disorders0/3620/1591/1570/3602/359
PericarditisCardiac disorders0/3620/1591/1570/3601/359
Epiploic appendagitisGastrointestinal disorders0/3620/1591/1570/3600/359
PapillitisGeneral disorders0/3620/1591/1570/3600/359
Respiratory tract infectionInfections and infestations1/3620/1591/1571/3600/359
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboPlacebo/Lebrikizumab (37.5 mg)Placebo/Lebrikizumab (125 mg)Lebrikizumab (37.5 mg)Lebrikizumab (125 mg)
AsthmaRespiratory, thoracic and mediastinal disorders146/36254/15961/157156/360184/359
NasopharyngitisInfections and infestations54/36222/15924/15772/36081/359
Upper respiratory tract infectionInfections and infestations33/36210/15917/15759/36067/359
BronchitisInfections and infestations25/36212/15912/15760/36048/359
SinusitisInfections and infestations21/3625/1598/15726/36034/359
HeadacheNervous system disorders28/3629/1595/15734/36029/359
InfluenzaInfections and infestations6/3626/1591/15728/36021/359
RhinitisInfections and infestations13/3621/15912/15724/36020/359
Back painMusculoskeletal and connective tissue disorders14/3624/1595/15722/36024/359
Rhinitis allergicRespiratory, thoracic and mediastinal disorders13/3626/1596/15724/3608/359

Baseline characteristics

The ITT population presented includes two subgroups: biomarker-high (participants with serum periostin levels ≥ 50 ng/mL or blood eosinophil count ≥ 300 cells/μL at Visit 1) and biomarker-low (participants with serum periostin levels \< 50 ng/mL and blood eosinophil count \< 300 cells/μL at Visit 1).

Age, Continuous
Age, Continuous(years)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Mean51.3 ± 12.451.3 ± 13.251.8 ± 12.651.2 ± 12.151.5 ± 12.149.0 ± 12.451.2 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Female166162178657270713
Male908977413734368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Hispanic or Latino283238121111132
Not Hispanic or Latino228219217949893949
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
American Indian or Alaska Native2210005
Asian403334166120
Native Hawaiian or Other Pacific Islander0010102
Black or African American2012797863
White191197209959486872
More than one race1010002
Unknown or Not Reported27211417
Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)(mL)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Mean1795 ± 5721785 ± 5411779 ± 5881982 ± 6241865 ± 5091918 ± 5171826 ± 566
Standardized Asthma Quality of Life Questionnaire (AQLQ) Score
Standardized Asthma Quality of Life Questionnaire (AQLQ) Score(Score on scale)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Mean4.23 ± 1.044.15 ± 1.044.16 ± 1.044.06 ± 1.124.22 ± 1.174.23 ± 0.964.18 ± 1.05
Asthma Control Questionnaire-5 (ACQ-5) Score
Asthma Control Questionnaire-5 (ACQ-5) Score(Score on scale)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
Mean2.67 ± 0.722.62 ± 0.722.61 ± 0.742.73 ± 0.852.59 ± 0.752.56 ± 0.742.63 ± 0.74
Baseline Use of inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA)
Baseline Use of inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA)(Participants)Biomarker-High: PlaceboBiomarker-High: Lebrikizumab 37.5 mgBiomarker-High: Lebrikizumab 125 mgBiomarker-Low: PlaceboBiomarker-Low: Lebrikizumab 37.5 mgBiomarker-Low: Lebrikizumab 125 mgTotal
ICS < 1000 µg/day or no LABA149135137546462601
ICS ≥ 1000 µg/day and LABA107116118524542480

1 further baseline measures are reported on the registry.

08

Study locations

181 sites
  • Alabama Clinical Research Associates
    Pell City, Alabama 35128, United States
  • Desert Sun Clinical Research LLC
    Tucson, Arizona 85710, United States
  • Allianz Medical and Research Center
    Fountain Valley, California 92708, United States
  • Allergy & Asthma Medical Group & Research Center, Pc
    Long Beach, California 90808, United States
  • Allergy Medical Clinic
    Los Angeles, California 90025, United States
  • CA Allergy & Asthma Med Grp
    Los Angeles, California 90025, United States
  • North Bay Clinical Trials
    Napa, California 94558, United States
  • Choc Psf, Amc
    Orange, California 92868, United States
  • Advances in Medicine
    Rancho Mirage, California 92270, United States
  • Allergy Assoc Medical Group
    San Diego, California 92108, United States
  • Bensch Research Associates
    Stockton, California 95207, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Waterbury Pulmonary Associates
    Waterbury, Connecticut 06708, United States
  • St. Francis Sleep; Allergy & Lung Institute
    Clearwater, Florida 33765, United States
  • Suncoast Research Group LLC
    Miami, Florida 33135, United States
  • Emerald Coast Research Associates
    Panama City, Florida 32405, United States
  • Allergy & Asthma Diagnostic; Treatment Center
    Tallahassee, Florida 32308, United States
  • Florida Pulmonary Research Institute, LLC
    Winter Park, Florida 32789, United States
  • Atlanta Allergy & Asthma Clini
    Woodstock, Georgia 30188, United States
  • Northeast Medical Research Associates, Inc
    North Dartmouth, Massachusetts 02747, United States
  • Midwest Clinical Research LLC
    St Louis, Missouri 63141, United States
  • Montana Medical Research LLC
    Missoula, Montana 59808, United States
  • Heartland Clinical Research Inc.
    Omaha, Nebraska 68134, United States
  • Asthma & Allergy Center, P.C.
    Papillion, Nebraska 68046, United States
  • Allergy & Asthma Associates
    Las Vegas, Nevada 89104, United States
  • Allergy & Asthma Research of Nj, Inc
    Mount Laurel, New Jersey 08054, United States
  • Atlantic Research Center, LLC
    Ocean City, New Jersey 07712, United States
  • Princeton Center For Clinical Research
    Skillman, New Jersey 08558, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Allergy & Asthma Center of NC
    High Point, North Carolina 27262, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Asthma & Allergy Center
    Toledo, Ohio 43617, United States
  • Cor Clinical Research
    Oklahoma City, Oklahoma 73103, United States
  • Allergy & Asthma Research Grp
    Eugene, Oregon 97401-7721, United States
  • Clinical Research Inst. of Southern Oregon, Pc
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center LLC - CRN
    Portland, Oregon 97202, United States
  • Asthma Allergy Pulm Associates
    Philadelphia, Pennsylvania 19107, United States
  • Grand View Hospital; Clinical Research Department
    Sellersville, Pennsylvania 18960, United States
  • Asthma Allergy Phys of RI
    Lincoln, Rhode Island 02865, United States
  • ADAC Research PA
    Greenville, South Carolina 29607, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Tekton Research Inc
    Austin, Texas 78745, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Pharmaceutical Research & Consulting, Inc.
    Dallas, Texas 75231, United States
  • Pioneer Research Solutions
    Houston, Texas 077099, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Quality Assurance Research Ctr
    San Antonio, Texas 78205, United States
  • O & O Alpan, LLC
    Fairfax, Virginia 22030, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23220, United States
  • Bellingham Asthma, Allergy & Immunology
    Bellingham, Washington 98225, United States
  • ASTHMA, Inc
    Seattle, Washington 98105, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Fundacion Faicep
    Buenos Aires, C1122AAK, Argentina
  • Centro Médico Dra de Salvo
    Buenos Aires, C1426ABP, Argentina
  • Instituto Ave Pulmo
    Mar del Plata, B7602DCK, Argentina
  • Centro Respiratorio Quilmes
    Quilmes, B1878FNR, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, T4000IAR, Argentina
  • Box Hill Hospital; Eastern Clinical Research Unit
    Box Hill, Victoria 3128, Australia
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
  • The Lung Institute of Western Australia; Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Inspiration Research
    Toronto, Ontario M5T 3A9, Canada
  • Albion Finch Medical Centre
    Toronto, Ontario M9V4B4, Canada
  • C.I.C. Mauricie
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Centro de Investigaciones Medicas Respiratorias
    Santiago, 7500692, Chile
  • Schonffeldt y Guerrero Limitada
    Santiago, 7500698, Chile
  • Fundacion Neumologica Colombiana
    Bogota DC, 11001, Colombia
  • Alergopraktik s.r.o.
    Jablonec nad Nisou, 466 01, Czechia
  • Interni A Pneumologicka Ambulance
    Jindřichův Hradec, 377 38, Czechia
  • MephaCentrum, a.s.
    Ostrava - Poruba, 708 68, Czechia
  • Alergologie Teplice, s.r.o.
    Teplice, 415 01, Czechia
  • Hopital Calmette; Pneumologie
    Lille, 59037, France
  • Hôpital Arnaud de Villeneuve
    Montpellier, 34295, France
  • CHU Nantes - Hôpital Laennec; Service de Pneumologie
    Nantes, 44093, France
  • Nouvel Hopital Civil; Pole de Pathologie Thoracique
    Strasbourg, 67091, France
  • Kenezy Korhaz Rendelointezet
    Debrecen, 4031, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Győr, 9024, Hungary
  • C.C.C. Hospital Chest Diseases
    Szeged, 6722, Hungary
  • Barzilai Medical Center; Pulmonary Inst.
    Ashkelon, 78306, Israel
  • Lady Davis Carmel Medical Center; Cardiovascular Medicine
    Haifa, 34362, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Meir Medical Center; Pulmonary Dept
    Kfar Saba, 4428164, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Azienda Ospedaliera Mater Domini Di Catanzaro
    Catanzaro, Calabria 88100, Italy
  • Università Degli Studi di Pisa - Ospedale di Cisanello Pisa
    Pisa, Tuscany 56124, Italy
  • Tosei General Hospital; Respiratory and Allergy Medicine
    Aichi, 489-8642, Japan
  • Kyushu Central Hospital
    Fukuoka, 815-8588, Japan
  • National Hospital Organization Mito Medical Center
    Higashiibaraki-gun, 311-3193, Japan
  • Oji General Hospital
    Hokkaido, 053-8506, Japan
  • National Hospital Organization Asahikawa Medical Center
    Hokkaido, 070-8644, Japan
  • Yokohama City Minato Red Cross Hospital
    Kanagawa, 231-8682, Japan
  • National Hospital Organization Tokyo National Hospital
    Kiyose-shi, 204-8585, Japan
  • Kochi Medical School Hospital
    Kochi, 783-8505, Japan
  • Oki Clinic
    Kodaira-shi, 187-0024, Japan
  • Takahashi Clinic
    Kokubunji-shi, 185-0014, Japan
  • Tono Chuo Clinic
    Mizunami-shi, 509-6134, Japan
  • Nagaoka Red Cross Hospital
    Nagaoka-shi, 940-2085, Japan
  • Niigata City General Hospital
    Niigata, 950-11977, Japan

Showing the first 100 of 181 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7. PubMed 33217063 ↗
  • N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma. BMJ Open Respir Res. 2019 Nov 11;6(1):e000406. doi: 10.1136/bmjresp-2019-000406. eCollection 2019. PubMed 31803473 ↗
  • Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5. PubMed 27616196 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Dec 2016, 41 months.

Results were first posted in Jul 2026, 9 years 6 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 41 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2013
First posted
Jun 3, 2013
StartActual
Jul 25, 2013
Primary completionActual
Dec 28, 2016
CompletionActual
Dec 28, 2016
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01867125
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 3, 2013
Start date
Jul 25, 2013
Primary completion
Dec 28, 2016
Completion
Dec 28, 2016
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion